CLP1R, GCGR, and GIPR are crucial drug targets for treating metabolic diseases.
CLP1R is involved in regulating insulin secretion; GCGR plays a key role in glucose homeostasis and is a major target for diabetes drug development; GIPR mediates incretin effects and influences energy metabolism.
Our company offers high-quality drug-target cells for these receptors, supporting high-throughput screening and activity validation to accelerate drug discovery for metabolic disorders.
